Benzinga
21 May 2026, 18:11 UTC · 17w ago
Verdict
Headline leans bullish. We score BMRN +0.90 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
BioMarin's Phase 3 CANOPY-HCH-3 study for VOXZOGO met its primary endpoint, showing a statistically significant 2.33 cm/year increase in annualized growth velocity for children with hypochondroplasia.
So whatPositive Phase 3 data for a drug targeting a market with no approved therapies is a major catalyst for valuation growth.
More positive than 99% of claims this week
BioMarin plans to submit a supplemental New Drug Application (sNDA) to the FDA for VOXZOGO in the third quarter of 2026.
Continue reading
5 related stories
More positive than 93% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
The FDA approved BioMarin's supplemental BLA for Palynziq, expanding its treatment for PKU to adolescents aged 12 and older.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 93% of ticker scores this week
The company reported positive Phase 3 study results for VOXZOGO and received FDA approval for a supplemental BLA for Palynziq.
More positive than 76% of ticker scores this week
Shares are trading higher following Canadian regulatory approval for generic amoxicillin.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
6h ago
+27.4%
Price agrees with the score
$63.94 vs $50.20 close before publication (May 20) · not market-adjusted
BMRN chart →
